1. Home
  2. EFC vs EOLS Comparison

EFC vs EOLS Comparison

Compare EFC & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EFC
  • EOLS
  • Stock Information
  • Founded
  • EFC 2007
  • EOLS 2012
  • Country
  • EFC United States
  • EOLS United States
  • Employees
  • EFC N/A
  • EOLS N/A
  • Industry
  • EFC Real Estate
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • EFC Finance
  • EOLS Health Care
  • Exchange
  • EFC Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • EFC 1.1B
  • EOLS 1.1B
  • IPO Year
  • EFC 2010
  • EOLS 2018
  • Fundamental
  • Price
  • EFC $13.33
  • EOLS $16.72
  • Analyst Decision
  • EFC Buy
  • EOLS Strong Buy
  • Analyst Count
  • EFC 6
  • EOLS 6
  • Target Price
  • EFC $13.85
  • EOLS $22.60
  • AVG Volume (30 Days)
  • EFC 778.3K
  • EOLS 593.5K
  • Earning Date
  • EFC 08-06-2024
  • EOLS 11-05-2024
  • Dividend Yield
  • EFC 11.73%
  • EOLS N/A
  • EPS Growth
  • EFC 160.50
  • EOLS N/A
  • EPS
  • EFC 1.27
  • EOLS N/A
  • Revenue
  • EFC $279,748,000.00
  • EOLS $237,260,000.00
  • Revenue This Year
  • EFC N/A
  • EOLS $34.62
  • Revenue Next Year
  • EFC $13.67
  • EOLS $32.97
  • P/E Ratio
  • EFC $10.44
  • EOLS N/A
  • Revenue Growth
  • EFC 33.01
  • EOLS 40.71
  • 52 Week Low
  • EFC $10.88
  • EOLS $7.44
  • 52 Week High
  • EFC $13.47
  • EOLS $17.59
  • Technical
  • Relative Strength Index (RSI)
  • EFC 58.94
  • EOLS 73.41
  • Support Level
  • EFC $12.93
  • EOLS $14.86
  • Resistance Level
  • EFC $13.21
  • EOLS $15.59
  • Average True Range (ATR)
  • EFC 0.15
  • EOLS 0.65
  • MACD
  • EFC -0.00
  • EOLS 0.09
  • Stochastic Oscillator
  • EFC 92.11
  • EOLS 85.85

About EFC Ellington Financial Inc.

Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: